CS263952B1 - Remedy with antiviral effect - Google Patents

Remedy with antiviral effect Download PDF

Info

Publication number
CS263952B1
CS263952B1 CS853018A CS301885A CS263952B1 CS 263952 B1 CS263952 B1 CS 263952B1 CS 853018 A CS853018 A CS 853018A CS 301885 A CS301885 A CS 301885A CS 263952 B1 CS263952 B1 CS 263952B1
Authority
CS
Czechoslovakia
Prior art keywords
formula
compounds
virus
cells
effect
Prior art date
Application number
CS853018A
Other languages
Czech (cs)
English (en)
Inventor
Antonin Rndr Drsc Holy
Ivan Ing Rosenberg
Original Assignee
Holy Antonin
Rosenberg Ivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holy Antonin, Rosenberg Ivan filed Critical Holy Antonin
Priority to CS853018A priority Critical patent/CS263952B1/cs
Priority to IL78553A priority patent/IL78553A/xx
Priority to US06/854,087 priority patent/US4724233A/en
Priority to AU56468/86A priority patent/AU586860B2/en
Priority to DK184186A priority patent/DK167342B1/da
Priority to PT82457A priority patent/PT82457B/pt
Priority to NZ215939A priority patent/NZ215939A/xx
Priority to EG241/86A priority patent/EG18436A/xx
Priority to GR861089A priority patent/GR861089B/el
Priority to PH33699A priority patent/PH23112A/en
Priority to CA000507510A priority patent/CA1272956A/fr
Priority to EP86105776A priority patent/EP0205826B1/fr
Priority to DE8686105776T priority patent/DE3684363D1/de
Priority to ZA863133A priority patent/ZA863133B/xx
Priority to AT86105776T priority patent/ATE73663T1/de
Priority to JP61097811A priority patent/JPH0692307B2/ja
Publication of CS263952B1 publication Critical patent/CS263952B1/cs
Priority to HK217296A priority patent/HK217296A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CS853018A 1985-04-25 1985-04-25 Remedy with antiviral effect CS263952B1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect
IL78553A IL78553A (en) 1985-04-25 1986-04-21 Therapeutic compositions of phosphonylmethoxyalkyl adenines
US06/854,087 US4724233A (en) 1985-04-25 1986-04-21 Therapeutical application of phosphonylmethoxyalkyl adenines
AU56468/86A AU586860B2 (en) 1985-04-25 1986-04-22 Therapeutical application of phosphonylmethoxyalkyl adenines
DK184186A DK167342B1 (da) 1985-04-25 1986-04-22 Terapeutisk praeparat til behandling af virussygdomme samt anvendelse af et 9-(fosfonylmetoxyalkyl)adeninderivat til fremstilling af praeparatet
EG241/86A EG18436A (en) 1985-04-25 1986-04-24 Therapeutical application of phosponylmethoxy-alkyl adenines
NZ215939A NZ215939A (en) 1985-04-25 1986-04-24 Phosphonyl methoxyadenine antiviral compositions
PT82457A PT82457B (pt) 1985-04-25 1986-04-24 Processo de preparacao de uma composicao farmaceutica com base em fosfonil-metoxi-alquil-adeninas com actividade antiviral
GR861089A GR861089B (en) 1985-04-25 1986-04-24 Therapeutic application of phosponylmethoxy alkyl ademines
PH33699A PH23112A (en) 1985-04-25 1986-04-24 Therapeutical application of phosphonylmethoxyalkyl adenines
CA000507510A CA1272956A (fr) 1985-04-25 1986-04-24 Utilisation therapeutique de phosphonylmethoxy-alkyl- adenines
EP86105776A EP0205826B1 (fr) 1985-04-25 1986-04-25 Phosphonylméthoxyalkyl-adénines pour le traitement de maladies à virus
DE8686105776T DE3684363D1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
ZA863133A ZA863133B (en) 1985-04-25 1986-04-25 Therapeutical application of phosphonylmethoxyalkyl adenines
AT86105776T ATE73663T1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
JP61097811A JPH0692307B2 (ja) 1985-04-25 1986-04-25 アデニン誘導体の治療的適用
HK217296A HK217296A (en) 1985-04-25 1996-12-19 Phosphonylmethoxy alkyl adenines for the treatment of virus diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Publications (1)

Publication Number Publication Date
CS263952B1 true CS263952B1 (en) 1989-05-12

Family

ID=5369042

Family Applications (1)

Application Number Title Priority Date Filing Date
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Country Status (17)

Country Link
US (1) US4724233A (fr)
EP (1) EP0205826B1 (fr)
JP (1) JPH0692307B2 (fr)
AT (1) ATE73663T1 (fr)
AU (1) AU586860B2 (fr)
CA (1) CA1272956A (fr)
CS (1) CS263952B1 (fr)
DE (1) DE3684363D1 (fr)
DK (1) DK167342B1 (fr)
EG (1) EG18436A (fr)
GR (1) GR861089B (fr)
HK (1) HK217296A (fr)
IL (1) IL78553A (fr)
NZ (1) NZ215939A (fr)
PH (1) PH23112A (fr)
PT (1) PT82457B (fr)
ZA (1) ZA863133B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
IL84477A (en) * 1986-11-18 1995-12-08 Bristol Myers Squibb Co History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them
US5284837A (en) * 1988-05-06 1994-02-08 Medivir Ab Derivatives of purine, process for their preparation and a pharmaceutical preparation
EP0353955A3 (fr) * 1988-08-02 1991-08-14 Beecham Group Plc Composés chimiques
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DE10399025I2 (de) * 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
WO1993007157A1 (fr) * 1991-10-11 1993-04-15 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic Derives acycliques antiviraux alcenyle et alkynyle de purine et de pyrimidine substitues par phosphonomethoxyalkyle
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JPH09506333A (ja) * 1993-09-17 1997-06-24 ギリアード サイエンシーズ，インコーポレイテッド 治療化合物の投薬方法
US5468752A (en) * 1994-04-04 1995-11-21 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
WO1995026734A1 (fr) * 1994-04-04 1995-10-12 Freeman William R Emploi de nucleosides de phosphonylemethoxyalkyle pour traiter la pression intra-oculaire elevee
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
CZ20022353A3 (cs) * 2000-01-07 2003-02-12 Universitaire Instelling Antwerpen Deriváty purinu, způsob jejich přípravy a jejich použití
KR100767432B1 (ko) 2000-07-21 2007-10-17 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법
IL159494A0 (en) * 2001-06-29 2004-06-01 Acad Of Science Czech Republic 6-2'-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
JP4332496B2 (ja) * 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
NZ536328A (en) * 2002-05-13 2007-11-30 Metabasis Therapeutics Inc Novel phosphonic acid based prodrugs of PMEA and its analogues
AU2003284800A1 (en) * 2002-11-12 2004-06-03 Tianjin Kinsly Pharmaceutical Co., Ltd. A new crystal form of adefovir dipivoxil and its composition
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
NZ543864A (en) 2003-06-16 2009-10-30 Leuven K U Res & Dev Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
RU2006138907A (ru) * 2004-06-08 2008-07-20 Метабазис Терапеутикс Синтез сложных циклических эфиров с применением кислоты льюиса
CN100338080C (zh) * 2004-06-16 2007-09-19 山东中科泰斗化学有限公司 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法
EP1778251B1 (fr) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Conjugues de phosphonate nucleosidique comme agents anti-vih
WO2006066074A2 (fr) 2004-12-16 2006-06-22 The Regents Of The University Of California Medicaments destines au poumon
WO2006130217A2 (fr) * 2005-04-01 2006-12-07 The Regents Of The University Of California Esters de phosphate de phosphonates de nucleosides substitues
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
PT2159224E (pt) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
WO2010110622A2 (fr) 2009-03-26 2010-09-30 Daewoong Pharmaceutical Co., Ltd. Nouvelles formes cristallisées de l'adéfovir dipivoxil et leurs procédés de préparation
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
BR112013014485B1 (pt) 2010-12-10 2021-03-30 Sigmapharm Laboratories, Llc Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
BR112015023705A8 (pt) 2013-03-15 2020-03-17 Univ California compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
WO2015038421A1 (fr) 2013-09-10 2015-03-19 Dow Corning Corporation Composants d'alliage eutectique de silicium résistants à l'usure et procédés de fabrication de ces derniers
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
WO2015195538A1 (fr) 2014-06-17 2015-12-23 Dow Corning Corporation Articles décoratifs façonnés constitués d'alliages eutectiques de silicium, et leurs procédés de production
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
PL3194411T3 (pl) 2014-09-15 2022-06-20 The Regents Of The University Of California Analogi nukleotydów
WO2017048956A1 (fr) 2015-09-15 2017-03-23 The Regents Of The University Of California Analogues nucléotidiques
MA42818A (fr) 2015-09-15 2018-07-25 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
EP3372227A1 (fr) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Formulation de comprimé d'adéfovir dipivoxil
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
JPS52105195A (en) * 1976-03-01 1977-09-03 Wellcome Found Substituted purine
US4230708A (en) * 1977-10-20 1980-10-28 Stichting Rega V.Z.W. Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS238038B1 (en) * 1983-10-07 1985-11-13 Antonin Holy Medical drug with antivirus effect

Also Published As

Publication number Publication date
PT82457B (pt) 1988-03-03
GR861089B (en) 1986-08-26
JPH0692307B2 (ja) 1994-11-16
ZA863133B (en) 1987-02-25
AU586860B2 (en) 1989-07-27
CA1272956A (fr) 1990-08-21
DK184186D0 (da) 1986-04-22
DE3684363D1 (de) 1992-04-23
EG18436A (en) 1993-02-28
IL78553A0 (en) 1986-08-31
DK184186A (da) 1986-10-26
PT82457A (en) 1986-05-01
EP0205826A2 (fr) 1986-12-30
NZ215939A (en) 1988-09-29
HK217296A (en) 1996-12-27
ATE73663T1 (de) 1992-04-15
EP0205826B1 (fr) 1992-03-18
US4724233A (en) 1988-02-09
EP0205826A3 (en) 1989-05-10
IL78553A (en) 1989-09-28
PH23112A (en) 1989-04-19
DK167342B1 (da) 1993-10-18
AU5646886A (en) 1986-10-30
JPS61275218A (ja) 1986-12-05

Similar Documents

Publication Publication Date Title
CS263952B1 (en) Remedy with antiviral effect
De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
De Clercq S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents
Clercq et al. A novel selective broad-spectrum anti-DNA virus agent
De Clercq et al. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds
US5321030A (en) Creatine analogs having antiviral activity
De Clercq Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and-pyrimidines
De Clercq et al. Selective in vitro and in vivo activities of 5-(2-haloalkyl) pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus
Soike et al. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys
Zakirova et al. Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro
CA2222154A1 (fr) Derives de l'acyclovir a usage topique
KEATING Antiviral agents
De Clercq The antiviral spectrum of (E)-5-(2-bromovinyl)-2′-deoxyuridine
AU623341B2 (en) Antiviral therapy for hepatitis b
EP0294443B1 (fr) Utilisation de nucleosides pour la fabrication d'un medicament destine aux traitements de maladies causees par un retrovirus ou par le virus de l'hepatite b
JPH0618786B2 (ja) 医薬組成物
PL207187B1 (pl) Pochodne 6-[2-(fosfonometoksy) alkoksy] pirymidyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te pochodne oraz ich zastosowanie
JPS59186985A (ja) ジメチルアミノメチレン化された抗ヘルペス化合物
Wingard et al. Activity of trifluorothymidine against cytomegalovirus
Machida et al. In vitro antiherpesviral activity of 5-alkyl derivatives of 1-β-d-arabinofuranosyluracil
CS238038B1 (en) Medical drug with antivirus effect
CA1328865C (fr) Composition et methode de traitement des infections par le virus hepatitique, au moyen de 1-(2'-desoxy-2'-fluro-b- d-arabino-furanosyl)-5-ethylurocycle
Ayisi et al. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses
Barnard et al. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses
Park et al. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20000425